

including *SMPD3*.⁴ *SMPD3*, which encodes nSMase2, is transcriptionally enriched in human committed progenitors relative to HSCs,⁴ suggesting a possible regulatory role in HSC self-renewal/lineage fate decisions. Hurwitz et al showed *SMPD3*-knockout (KO) murine HSPCs had competitive repopulation advantage relative to control-KO HSPCs, and GW4869-treated human HSPCs engrafted better than control-treated HPSCs in xenotransplantation assays.¹ Notably, quantitative mass spectrometry on EVs isolated from human *SMPD3*-KO HSPCs compared with control HSPCs showed a depletion of key proteins associated with myeloid lineage transcription and signaling factors, such as PU.1 and colony-stimulating factor 1, as well as mitochondrial protein and DNA cargo.¹ These data point directly to the importance of nSMase2 in HSPC fate decisions, but also raise the question of whether it is directly attributed to its sphingomyelinase activity and blocking of hydrolyzation of SM to ceramide (a precursor to sphingosine) and phosphocholine to activate a “lipid biostat.”⁴ Interestingly, the authors did not find overall global depletion of ceramide nor SM accumulation with GW4869 treatment.¹ However, lipid quantitation by mass spectrometry was performed on a bulk murine HSPC subpopulation expanded for 14 days. The authors noted that ceramide/SM ratios for some specific long-chain acyl species were perturbed. Previous lipidomic studies have shown that some sphingolipid species are differentially enriched in HSC-enriched cells relative to committed progenitors in both the human and mouse settings at steady state.² Thus, future low-input lipidomic studies on highly refined stem and progenitor subsets should further shed light on the complexity of sphingolipid metabolism and its functional role in HSC vs committed progenitor subsets.

Finally, drug resistance in leukemia stem cells is a perplexing issue that has been linked to proteostatic stress response programs and mitochondrial metabolism/metabolic reprogramming, including of sphingolipids.² Thus, future studies integrating the findings from this study on HSC fitness to cancer could have major translational implications for proteostasis programs, EV secretion, and metabolic reprogramming to disrupt drug resistance in hematological malignancies and solid tumors.^{2,10}

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

- Hurwitz SN, Jung SK, Kobulsky DR, et al. Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response. *Blood*. 2023;142(20):1708-1723.
- Lim INX, Nagree MS, Xie SZ. Lipids and the cancer stemness regulatory system in acute myeloid leukemia. *Essays Biochem*. 2022; 66(4):333-344.
- van Galen P, Mbong N, Kreso A, et al. Integrated stress response activity marks stem cells in normal hematopoiesis and leukemia. *Cell Rep*. 2018;25(5):1109-1117.e5.
- Xie SZ, Garcia-Prat L, Voisin V, et al. Sphingolipid modulation activates proteostasis programs to govern human hematopoietic stem cell self-renewal. *Cell Stem Cell*. 2019;25(5):639-653.e7.
- Essandoh K, Yang L, Wang X, et al. Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. *Biochim Biophys Acta*. 2015;1852(11):2362-2371.
- García-Prat L, Kaufmann KB, Schneiter F, et al. TFEB-mediated endolysosomal activity controls human hematopoietic stem cell fate. *Cell Stem Cell*. 2021;28(10):1838-1850.e10.
- Li J, Wang X, Ding J, et al. Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell. *Acta Pharm Sin B*. 2022;12(6):2808-2831.
- Che JLC, Bode D, Kucinski I, et al. Identification and characterization of in vitro expanded hematopoietic stem cells. *EMBO Rep*. 2022;23(10):e55502.
- Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. *Blood*. 2022;140(15):1686-1701.
- Lv X, Lu X, Cao J, et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. *Science*. 2023;381(6662):eabn4180.

<https://doi.org/10.1182/blood.2023022497>

© 2023 by The American Society of Hematology

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Comment on *Ang et al*, page 1724

5'-UTR mRNA splicing determines CD20 levels


Marek Mraz | CEITEC Masaryk University and University Hospital Brno

In this issue of *Blood*, *Ang et al*¹ show that human CD20 messenger RNA (mRNA) undergoes alternative splicing to generate distinct 5' untranslated region (5'-UTR) variants, which determine the cell-surface CD20 levels in malignant B cells and the interpatient variability in the expression of this therapeutic target. These variants can also be used as an escape mechanism from anti-CD20 therapies.

The approval of rituximab, the anti-CD20 antibody, by the Food and Drug Administration in 1997 was a conceptual breakthrough for the treatment of “mature” B-cell malignancies. Based on rituximab’s success, newly engineered anti-CD20 monoclonal antibodies have been manufactured, followed by the development of anti-CD20 chimeric antigen receptor T cells and anti-CD20/CD3 bispecific T cell engagers (such as mosunetuzumab). Although CD20 is an ideal therapeutic target, it is still unclear how its expression is regulated in normal or in malignant B cells. The need to understand CD20 regulation is underscored by the surprising observation that B-cell receptor inhibitors greatly reduce

CD20 levels by interfering with its transcriptional regulation.^{2,3} Rituximab efficacy is highly dependent on cell-surface CD20 levels,^{4,5} and the reduction of CD20 levels at least partially explains the resistance to anti-CD20 antibodies and the lack of clinical benefit of the addition of rituximab to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).⁶

Several different *MS4A1* mRNA transcripts (encoding CD20) were identified when the structure of *MS4A1* was characterized in 1989.⁷ Tedder et al⁷ noted that the dominant *MS4A1* mRNA variant is 2.8 kilobase long and uses all 8 exons encoded by *MS4A1*, whereas a second



The 5'-UTR splicing variants of *MS4A1* (encoding CD20) and their frequency in mature B-cell malignancies. (A) The transcription of *MS4A1* is regulated by multiple cell signals and transcription factors (TFs). Four 5'-UTR isoforms (V1-V4) of *MS4A1* have been identified resulting from distinct splicing events between exon 1 and 3 (internal splice site), but all have identical coding sequences (translation start codon is localized within exon 3). The V3 and V4 represent translation proficient variants, whereas inefficient translation of V1 and V2 transcripts is rate-limiting for CD20 protein production. The V1 and V2 variants harbor multiple upstream open reading frames and a stem-loop secondary structure containing binding sites for Sam68 protein. (B) The frequency of V1-4 variants of *MS4A1* in samples from multiple cohorts of B-cell malignancies (FL, $n = 2$; endemic BL, $n = 3$; DLBCL, $n = 4$; CLL, $n = 3$). The V1 and V3 represent together >90% of *MS4A1* isoforms, and their ratio has a wide distribution within samples from the same diagnosis. Professional illustration by Patrick Lane, ScEYence Studios.

variant is 263 nucleotides shorter with the exon 1 spliced into an internal 3' splice site within exon 3, thereby skipping exon 2. However, all identified transcripts were shown to be translated into identical full-length CD20 proteins as the translation start codon is localized

within exon 3, and the importance of these splicing variants remained unclear. Moreover, other *MS4A1* alternative splice variants that involve the open reading frame (exon 3-8) were identified in malignant or Epstein-Barr virus (EBV) transformed B cells, some of them

encoding truncated CD20 protein, resulting in impaired efficacy of anti-CD20 antibodies.⁸

To identify *MS4A1* mRNA isoforms, Ang et al performed Nanopore long-read sequencing on Raji cell lines and found

three 5'-UTR isoforms corresponding to previously identified transcripts (V1, V2, and V3) and also a 4th rarer undescribed 5'-UTR variant (V4) (see figure panel A). Similar to the observations by Tedder et al,⁷ all of these mRNA isoforms had distinct 5'-UTRs with a splicing event occurring between exon 1 and exon 3 (or internal splice site in exon 3) but had identical coding sequences. The authors used publicly available short-read RNA sequencing data from various B-cell malignancies (B-cell acute lymphoblastic leukemia, endemic Burkitt lymphoma [BL], CLL, diffuse large B-cell lymphoma [DLBCL], and follicular lymphoma [FL]) and performed the analysis of exon-exon junctions for the V1-4 variants. This revealed that V1 and V3 together represent >90% of *MS4A1* isoforms and the ratio of V3 to V1 has a wide distribution within samples with the same diagnosis. Among the B-cell neoplasms, EBV⁺ endemic BL stood out as having a relatively higher V3:V1 ratio, and this V1-to-V3 shift was recapitulated when normal B cells were infected by EBV in vitro. The change in isoforms toward V3 (or V4) after EBV infection cooccurred with elevation in cell-surface CD20 levels, and this is especially notable since EBV infection downmodulated the total *MS4A1* mRNA levels. This led the authors to hypothesize that although the V1 and V3 *MS4A1* mRNA isoforms have identical coding sequences, they possess distinct 5'-UTRs that can alter mRNA turnover and/or translation, a mechanism previously noted by the same laboratory for CD22.⁹ Indeed, relative to V3 and V4, a smaller fraction of V1 and V2 molecules was associated with polysomes reflecting decreased propensity for translation. Overexpression of engineered vectors with all variants (V1-4) demonstrated that inefficient V1 and V2 transcript translation is rate-limiting for CD20 protein production. In some of these experiments, the overexpression of isolated V1 isoform in a cell line did not lead to any detectable CD20 protein levels, whereas V3 isoform led to a massive increase in CD20 protein, suggesting a major role for the V3:V1 ratios in determining cell surface CD20 levels. Inefficient V1 (and V2) translation implied the presence of repressive 5'-UTR elements. Detailed analysis revealed that the exon 3a sequence contained in V1 and V2

isoforms harbors multiple upstream open reading frames (uORFs) and that the exon 3a-b boundary immediately upstream of the *MS4A1* start codon also forms a stem-loop secondary structure (see figure panel A). Deletion mutants and engineered variants with mutated start codons in uORFs showed that these elements are responsible for the negligible CD20 protein produced from V1 and V2 mRNAs. The exon 3a loop structure contains binding sites for Sam68, a splicing factor known to bind to AU-rich sequences. Sam68 knock-down in Raji cells resulted in the redistribution of 5'-UTR variants, suggesting that Sam68 is at least partly responsible for selecting *MS4A1* isoforms.

Altogether, more than 30 years after the work by Tedder et al,⁷ this study deciphered the effect of *MS4A1* mRNA isoforms on this mRNA's translation efficacy. The evolutionary importance of this regulatory mechanism remains unknown. Likewise, it is not known if this mechanism also applies to any of the other 18 members of this gene family. Practically, the findings reported here have direct implications for understanding why some B-cell malignancies or individual patients have lower pre-therapy CD20 levels. Indeed, screening V1-4 isoforms in large cohorts of patients' samples revealed that some have a near absence of translation-proficient V3 variant (see figure panel B). The CD20 levels are heterogeneous within the intraclonal cell subpopulations in an individual patient,¹⁰ and it remains to be determined whether V3:V1 ratios change during B-cell exposure to signals known to regulate CD20 levels on malignant B cells, such as interleukin-4 or SDF1 chemokine.^{2,3} Moreover, changes in V3:V1 might be a potential escape mechanism for anti-CD20 therapies. Indeed, Ang et al observed a V3-to-V1 shift in 2 out of 4 patients with mosunetuzumab-resistant follicular lymphoma.

Finally, the authors used morpholino antisense oligonucleotides to enhance CD20 translation by modulating alternative splicing of noncoding exons of *MS4A1*. Such treatment induced shifts in *MS4A1* splicing, namely increasing V3 and V4 variants and elevated CD20 protein. This resulted in a >10-fold decrease in rituximab inhibitory concentration in 2 out

of 3 tested cell lines, providing the first steps toward RNA-based therapeutics.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Ang Z, Paruzzo L, Hayer KE, et al. Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. *Blood*. 2023; 142(20):1724-1739.
2. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. *Blood*. 2016;128(12):1609-1613.
3. Sandova V, Pavlasova GM, Seda V, et al. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K inhibitor idelalisib. *Haematologica*. 2021;106(11):2995-2999.
4. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. *Clin Cancer Res*. 2006; 12(13):4027-4035.
5. Borsky M, Hrabcakova V, Novotna J, et al. Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion. *Leuk Res*. 2021;111:106684.
6. Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood*. 2019;133(10): 1011-1019.
7. Tedder TF, Klejman G, Schlossman SF, Saito H. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). *J Immunol*. 1989;142(7): 2560-2568.
8. Gamonet C, Bole-Richard E, Delherme A, et al. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. *Exp Hematol Oncol*. 2015;5:7.
9. Zheng S, Gillespie E, Naqvi AS, et al. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies. *Blood Cancer Discov*. 2022;3(2):103-115.
10. Pavlasova G, Borsky M, Svobodova V, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. *Leukemia*. 2018;32(9):2028-2031.

<https://doi.org/10.1182/blood.2023022305>

© 2023 by The American Society of Hematology